Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v1-EN
Language French English
Date Updated 2024-07-02 2024-06-10
Drug Identification Number 02491680 02491680
Brand name HYDROMORPHONE HYDROCHLORIDE INJECTION, USP HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Common or Proper name HYDROMORPHONE HYDROCHLORIDE INJECTION, USP HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients HYDROMORPHONE HYDROCHLORIDE HYDROMORPHONE HYDROCHLORIDE
Strength(s) 10MG 10MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 1 mL 1 mL
ATC code N02AA N02AA
ATC description OPIOIDS OPIOIDS
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date
Actual start date 2024-06-07 2024-06-07
Estimated end date 2024-06-28 2024-06-28
Actual end date 2024-06-28
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be encountering a supply interruption on our HYDROmorphone Hydrochloride Injection, USP 10 mg/mL SD Vial 1 mL effective June 7, 2024 until June 28, 2024. Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be encountering a supply interruption on our HYDROmorphone Hydrochloride Injection, USP 10 mg/mL SD Vial 1 mL effective June 7, 2024 until June 28, 2024.
Health Canada comments